Trial reportUpdates in surgery2025
Assessment of PTeye™ versus FLUOBEAM® LX for parathyroid adenomas: a pilot case-control study.
Trial report in Updates in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identifying the parathyroids is compulsory for success of parathyroidectomy for parathyroid adenoma. The aim of the present study is to evaluate and compare the efficacy of PTeye™ and FLUOBEAM® LX in identifying parathyroid adenomas. Patients undergoing parathyroidectomy due to a parathyroid adenoma were enrolled prospectively in this study and were randomly included to Group A (PTeye™) or Group B (FLUOBEAM® LX). After intraoperative identification of parathyroid adenomas and before tissue dissection (minute 0), we evaluated the efficacy of both devices in confirming the adenomas. We re-evaluated devices' efficacy in minutes 1, 3 and 5 during tissue dissection and before adenoma excision. All PAs were confirmed and identified with PTeye™, while FLUOBEAM® LX could not identify 3/20 adenomas (15%). PTeye™ confirmed parathyroid tissue in less than 1 min in 13 cases (65%), in < 3 min in 7 (35%), whereas FLUOBEAM® LX identified 4 adenomas in < 3 min (20%), in < 5 min 9 adenomas (60%) and > 5 min in 4 (20%). PTeye™ and FLUOBEAM® LX are both useful tools in confirming parathyroid tissue intraoperatively. PTeye™ confirmed the suspected adenoma earlier before tissue dissection, while FLUOBEAM® LX demands tissue dissection as it identifies the normal parathyroid tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.